EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Thyroid transcription factor 1 ( TTF ‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

Xiaosheng Ding, Weiwei Shi, Bingxuan Han, Hanxiao Chen iD, Jia Li, Juan An, Lili Zhou, Weiran Xu, Hui Shi, Xixi Zheng, Yichun Hua, Xiaoyan Li iD

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Xiaosheng Ding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Mutation, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Education Commission-Beijing Natural Science Foundation Union Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The absence of thyroid transcription factor 1 (TTF‐1) is associated with a lower frequency of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LUAD). The aim of this study was to assess the impact of TTF‐1 expression on the clinical response to EGFR‐tyrosine kinase inhibitor (TKI) treatment in patients with advanced LUAD.

Methods

The data of patients with advanced LUAD who were admitted to the Beijing Tiantan Hospital and Peking University Cancer Hospital (China) between April 2009 and May 2023 was retrospectively analyzed.

Results

A total of 227 patients diagnosed with advanced LUAD were included, of which 28.2% (64/227) had TTF‐1‐negative adenocarcinoma, while 54.6% (124/227) harbored EGFR mutations. Negative TTF‐1 expression significantly correlated with male sex (68.8% vs. 42.3%, p < 0.001), history of heavy smoking (57.8% vs. 36.2%, p = 0.003), poorly differentiated tumors (86.5% vs. 43.2%, p < 0.001), and lower frequency of EGFR mutations (26.6% vs. 65.6%, p < 0.001) compared with TTF‐1 positivity. Multivariable logistic regression showed that low prevalence of EGFR mutations ( p < 0.001) and male sex ( p = 0.006) were independent predictive factors for the negative expression of TTF‐1. Patients lacking TTF‐1 also exhibited worse overall response rate (ORR; 23.5% vs. 54.2%, p = 0.019), disease control rate (DCR; 58.8 % vs. 89.7%, p = 0.003), and median progression‐free survival (PFS; 2.9 vs. 11.6 months, p < 0.001) following treatment with EGFR‐TKIs compared to the TTF‐1‐positive patients with EGFR mutations.

Conclusions

Patients with TTF‐1‐negative and EGFR ‐mutant LUAD show a diminished response to EGFR‐TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungMutationLung NeoplasmsProtein Kinase InhibitorsThyroid Nuclear Factor 1Biomarkers, TumorHumansMaleFemaleErbB ReceptorsMiddle AgedAgedRetrospective StudiesPrognosisAdult

Stichwörter der Autor:innen

EGFR tyrosine kinase inhibitorefficacyepidermal growth factor receptorlung adenocarcinomathyroid transcription factor 1

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanThyroid Nuclear Factor 1NKX2-1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Oncology, PLA General Hospital, Beijing, China.
  • Department of Sport Rehabilitation, Shanxi Medical University, Taiyuan, China.
  • Department of Physical Education, Shanxi Medical University, Taiyuan, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Hanxiao Chen, Xiaoyan Li

Förderung

  • Beijing Municipal Education Commission-Beijing Natural Science Foundation Union Program
  • National Natural Science Foundation of China

Zitieren

APA

Ding, X., Shi, W., Han, B., Chen, H., Li, J., An, J., Zhou, L., Xu, W., Shi, H., Zheng, X., Hua, Y., & Li, X. (2023). Thyroid transcription factor 1 ( TTF ‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15079

Vancouver

Ding X, Shi W, Han B, Chen H, Li J, An J, et al. Thyroid transcription factor 1 ( TTF ‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15079

BibTeX
@article{Ding2023,
  author = {Ding, Xiaosheng and Shi, Weiwei and Han, Bingxuan and Chen, Hanxiao and Li, Jia and An, Juan and Zhou, Lili and Xu, Weiran and Shi, Hui and Zheng, Xixi and Hua, Yichun and Li, Xiaoyan},
  title = {Thyroid transcription factor 1 ( TTF ‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15079}
}
Kostenlos starten →